SPRO

Business Context and Reporting Period

This Form 8-K reports on the 2019 Annual Meeting of Stockholders held by Spero Therapeutics, Inc. on June 5, 2019. The company is incorporated in Delaware and its common stock trades on The Nasdaq Global Select Market under the symbol SPRO.

Key Financial Metrics

The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance actions and voting results.

Material Changes and Voting Results

A quorum of 12,195,465 shares (70% of the 17,422,878 eligible shares) was present at the meeting. The following actions were taken:

• Director Elections: Patrick Vink, M.D., and Frank E. Thomas were reelected as Class II directors until the 2022 annual meeting.
• Accounting Firm Ratification: PricewaterhouseCoopers LLP was ratified as the independent registered public accounting firm for the fiscal year ending December 31, 2019.

Guidance, Outlook, and Risks

The filing text does not provide a clear value for guidance, outlook, management commentary, risks, contingencies, or unusual items.

Key Facts for Investor Verification

• Verify the total number of shares eligible to vote (17,422,878) against the company's most recent capitalization table.
• Confirm the tenure of the reelected directors (Patrick Vink and Frank E. Thomas) extends through the 2022 annual meeting.
• Note the significant number of broker non-votes (3,787,972) on director elections, indicating shares held by brokers that did not receive voting instructions.
• Review the full proxy statement for detailed biographies of directors and the rationale for the auditor selection.